Key facts
- Ethermed’s last known valuation is $47.4M (Apr 2026).
- It has raised $16.9M; the latest was Early Stage VC ($16.9M) in Apr 2026.
- Notable investors include MassChallenge, Gaingels, Jumpstart Ventures, Enfield Capital Partners, Blue Marlin Partners (Washington) — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Ethermed
- ·The full record, as it builds
Funding rounds
No funding rounds for Ethermed are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ethermed
Developer of an artificial intelligence-based automation platform intended for prior authorization management purposes. The company's platform intercepts physician orders from electronic health record systems, extracts clinical data to determine specific payer requirements, performs evidence-based justification matching, and automatically populates and submits digital authorization forms directly to payers, enabling healthcare providers and insurance organizations to eliminate manual administrative paperwork, reduce treatment delays, and increase first-pass approval rates across diverse medical workflows.
- Sector
- Healthcare
- HQ
- Philadelphia, PA, United States
- Founded
- 2021
- Employees
- 29
- Website
- ethermed.ai/
- Ownership
- Privately Held (backing)
Ethermed doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ethermed shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ethermed in its N-PORT filings yet. We sweep new filings monthly.